Insights Into Chronic Lymphocytic Leukemia (CLL) 2025
Perspectives of community physicians on the treatment of CLL
Southeast – March 22, 2025
Faculty Chair
Jean Koff, MD
Winship Cancer Institute, Atlanta, GA, USA
Central – April 4, 2025
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Southwest – May 3, 2025
Faculty Chair
Andrew Lipsky, MD
Herbert Irving Comprehensive Cancer Center, New York, NY, USA
Florida – August 9, 2025
Faculty Chair
Alvaro Alencar, MD
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Phoenix, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Orlando, FL
- Florida
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of CLL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, and BR
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
